Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
HybriMat is a German medical technology company specializing in the development of innovative, bioresorbable implant materials for orthopedic applications. The company's core technology focuses on hybrid materials that combine the mechanical strength of magnesium alloys with specialized coatings or polymer components to control degradation rates and promote bone healing. By utilizing bioresorbable materials, HybriMat aims to eliminate the need for secondary surgeries to remove permanent metal implants, thereby reducing patient risk and healthcare costs. Their products are primarily targeted at osteosynthesis and the treatment of bone fractures where temporary stabilization is required during the natural healing process.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on HybriMat.